Journal of Advances in Drug Research

ISSN: 2230-7761
www.jadr.co.in

Volume 17, Issue 04 | Received 12.09.2026 | Accepted 14.09.2026 | Online 19.09.2026

PHARMACOKINETIC AND PHARMACODYNAMIC OPTIMIZATION OF H. PYLORI ERADICATION THERAPY IN PATIENTS WITH ANTIBIOTIC-RESISTANT H. PYLORI INFECTION

Tolibov Farrux Farhodivich
tolibovf1@gmail.com
orcid.org/0009-0001-0186-8499
Asia International University, Bukhara, Uzbekistan

Annotation

Helicobacter pylori infection remains one of the most important chronic bacterial infections worldwide and is strongly associated with chronic gastritis, peptic ulcer disease, gastric mucosa-associated lymphoid tissue lymphoma, and gastric cancer. The effectiveness of eradication therapy has progressively been challenged by increasing antimicrobial resistance, particularly to clarithromycin, metronidazole, and fluoroquinolones. Consequently, treatment optimization requires not only appropriate antimicrobial selection but also a better understanding of pharmacokinetic (PK) and pharmacodynamic (PD) principles.

Pharmacokinetic factors determine drug exposure at the relevant biological site and include absorption, distribution, metabolism, and elimination. In *H. pylori* infection, however, systemic exposure alone does not fully predict therapeutic success. Intrabal gastric exposure, gastric pH, drug stability in the acidic environment, penetration into gastric mucus, bacterial susceptibility, and the duration of exposure are also important. Pharmacodynamic principles describe the relationship between drug exposure and antimicrobial effect. Amoxicillin is traditionally considered a time-dependent antimicrobial, making sustained exposure particularly important, whereas other agents used against *H. pylori* may demonstrate different exposure-response relationships. Acid suppression is also pharmacodynamically important because elevation of intragastric pH can alter bacterial physiology and improve the activity of several antimicrobial agents.

The pharmacology of acid-suppressive therapy is particularly relevant. Proton pump inhibitors are affected by CYP2C19-mediated metabolism, resulting in clinically relevant interindividual variation in acid suppression. Potassium-competitive acid blockers provide a different pharmacological approach and can achieve strong and sustained acid suppression, potentially improving the pharmacodynamic environment for antimicrobial therapy. Current international guidelines emphasize the importance of local resistance patterns, previous antibiotic exposure, susceptibility-guided treatment when available, adherence, adequate treatment duration, and confirmation of eradication. A pharmacokinetic/pharmacodynamic framework therefore provides a rational basis for understanding treatment failure and for developing more effective strategies against antibiotic-resistant *H. pylori*.

Journal of Advances in Drug Research

ISSN: 2230-7761
www.jadr.co.in

Volume 17, Issue 04 | Received 12.09.2026 | Accepted 14.09.2026 | Online 19.09.2026

Keywords: *Helicobacter pylori*; antimicrobial resistance; pharmacokinetics; pharmacodynamics; acid suppression; amoxicillin; proton pump inhibitors; potassium-competitive acid blockers; eradication therapy; antimicrobial susceptibility.

1. Introduction

Helicobacter pylori is a spiral-shaped, Gram-negative, microaerophilic bacterium that colonizes the gastric mucosa. Persistent infection produces chronic gastric inflammation and is associated with a broad clinical spectrum ranging from asymptomatic gastritis to peptic ulcer disease and gastric malignancy. Because of its established role in gastric carcinogenesis, international consensus recommendations consider *H. pylori* an infectious disease requiring appropriate treatment when infection is identified.

Successful eradication depends on several interacting factors. These include bacterial susceptibility, antimicrobial exposure, gastric physiology, adherence, treatment duration, prior antibiotic use, and the characteristics of the acid-suppressive agent used in the regimen. Increasing resistance has become one of the principal causes of eradication failure. A large systematic review and meta-analysis published in 2024, incorporating more than 47,000 *H. pylori* isolates from 36 countries, demonstrated substantial geographical variation in primary resistance and an overall increasing trend for commonly used antibiotics during the preceding decade.

The traditional approach to eradication therapy has therefore evolved from simple antibiotic combinations toward more individualized treatment strategies. The 2024 American College of Gastroenterology guideline emphasizes resistance-aware treatment selection and identifies optimized bismuth quadruple therapy as the preferred empiric regimen when susceptibility is unknown in treatment-naïve patients, while also recognizing nontraditional approaches involving rifabutin or potent acid suppression in appropriate clinical contexts.

Within this changing therapeutic landscape, pharmacokinetics and pharmacodynamics provide an important conceptual framework. PK describes what the body does to a drug, whereas PD describes what the drug does to the microorganism or biological target. In *H. pylori* eradication, treatment success depends on obtaining adequate antimicrobial exposure at the gastric mucosal site while maintaining appropriate pharmacodynamic activity against the infecting strain.

2. Pharmacokinetic Principles in *H. pylori* Eradication

Pharmacokinetics is conventionally described through four fundamental processes:
absorption → distribution → metabolism → elimination.
For antimicrobial therapy against *H. pylori*, these processes determine systemic exposure, but systemic pharmacokinetics represents only part of the therapeutic equation. The bacterium is located primarily within the gastric mucus layer and in close association with gastric epithelial surfaces. Consequently, drug penetration into the gastric environment and preservation of antimicrobial activity under acidic conditions are particularly important.
Several characteristics influence effective exposure:

- drug absorption after oral administration;
- gastric and intestinal distribution;
- penetration into gastric mucus;
- chemical stability at low pH;

Journal of Advances in Drug Research
ISSN: 2230-7761
www.jadr.co.in
Volume 17, Issue 04 Received 12.09.2026 Accepted 14.09.2026 Online 19.09.2026

- hepatic metabolism;
- renal or biliary elimination;
- plasma and tissue half-life;
- frequency and timing of administration.

Older pharmacological analyses of *H. pylori* eradication therapy emphasized that antimicrobial agents have markedly different pharmacological properties. In particular, amoxicillin has traditionally been characterized as a time-dependent antibiotic, whereas clarithromycin, metronidazole, tetracyclines, and fluoroquinolones show different exposure-response characteristics.

This distinction is clinically relevant because increasing the dose of a drug does not necessarily produce a proportional increase in antimicrobial effect. The relevant objective is adequate exposure relative to the susceptibility of the organism and the pharmacodynamic characteristics of the drug.

3. Pharmacodynamics and Exposure-Response Relationships

Pharmacodynamics evaluates the relationship between antimicrobial exposure and antibacterial effect. Common PK/PD concepts used in antimicrobial pharmacology include:

- **time above the minimum inhibitory concentration (MIC);**
- **maximum concentration relative to MIC (Cmax/MIC);**
- **area under the concentration-time curve relative to MIC (AUC/MIC);**
- post-antibiotic effect.

The relevance of these parameters differs among antibiotic classes.

Experimental pharmacodynamic research involving *H. pylori* has demonstrated that antimicrobial agents may differ substantially in their effects on bacterial viability, morphology, intracellular ATP, and regrowth after exposure. Amoxicillin, for example, has demonstrated important time-related pharmacodynamic characteristics, whereas other agents may show a different exposure-response relationship.

Consequently, antimicrobial efficacy should not be interpreted simply as a function of the administered dose. It depends on the interaction between:

drug exposure + bacterial susceptibility + duration of exposure + gastric environment.

This is particularly important when the organism has elevated MIC values. As resistance increases, a previously adequate exposure may no longer produce sufficient pharmacodynamic activity.

4. The Importance of Gastric Acid Suppression

One of the most distinctive features of *H. pylori* pharmacotherapy is the importance of gastric acid suppression. Proton pump inhibitors (PPIs) are not simply supportive medications; they can alter the biological environment in which antibacterial treatment occurs.

H. pylori adapts to gastric acidity through several physiological mechanisms. Raising intragastric pH can influence bacterial growth and may increase the effectiveness of certain antimicrobials. Therefore, adequate and sustained acid suppression can be considered a pharmacodynamic component of eradication therapy.

The pharmacokinetics of PPIs are influenced substantially by CYP2C19-mediated metabolism. Genetic polymorphisms in CYP2C19 lead to variation in PPI exposure and consequently in the degree of acid suppression achieved. Patients who metabolize certain PPIs more rapidly may achieve less profound acid suppression than individuals with slower

Journal of Advances in Drug Research
ISSN: 2230-7761
www.jadr.co.in
Volume 17, Issue 04 Received 12.09.2026 Accepted 14.09.2026 Online 19.09.2026

metabolism. A meta-analysis of PPI-based *H. pylori* therapy found associations between CYP2C19 genotype, PPI pharmacology, and eradication outcomes.

These observations explain why apparently identical treatment regimens can produce different outcomes among individuals.

5. Potassium-Competitive Acid Blockers and Pharmacodynamic Optimization

Potassium-competitive acid blockers (PCABs), including vonoprazan, represent a different approach to acid suppression. Unlike conventional PPIs, which require activation in the acidic environment of the parietal cell canaliculus, PCABs directly inhibit the gastric H+/K+-ATPase through competitive interaction with the potassium-binding site.

The pharmacological consequences include rapid onset of acid suppression and sustained elevation of intragastric pH. This may create a more stable pharmacodynamic environment for antimicrobial treatment.

Recent clinical studies have investigated vonoprazan-amoxicillin dual therapy and different amoxicillin administration strategies. A 2024 multicenter randomized trial evaluated alternative dosing approaches and demonstrated clinically meaningful eradication rates, supporting the concept that the interaction between strong acid suppression and antibacterial exposure is an important area of pharmacological research.

Another randomized study examined different amounts of amoxicillin exposure in vonoprazan-based therapy and found broadly comparable efficacy between the evaluated strategies, emphasizing that optimization requires consideration of the entire PK/PD system rather than a single drug dose.

These findings support the concept that **acid suppression can modify the pharmacodynamic environment in which antimicrobial therapy operates**.

6. Pharmacological Characteristics of Amoxicillin

Amoxicillin is a beta-lactam antimicrobial widely used in *H. pylori* treatment. Its antibacterial activity results from interference with bacterial cell-wall synthesis through binding to penicillin-binding proteins.

From a pharmacodynamic perspective, amoxicillin is generally classified as a **time-dependent antimicrobial**. Its effectiveness is therefore related substantially to maintaining adequate exposure relative to the organism's susceptibility.

Importantly, resistance to amoxicillin remains relatively uncommon compared with resistance to several other antibiotics used for *H. pylori*. Nevertheless, low resistance does not automatically guarantee effective eradication. Insufficient exposure, poor adherence, unfavorable gastric conditions, or an inappropriate combination of agents may still contribute to treatment failure.

Recent studies of vonoprazan-amoxicillin therapy have specifically investigated how alterations in amoxicillin administration affect eradication. These studies illustrate a broader pharmacological principle: **effective antimicrobial therapy depends on maintaining an appropriate exposure profile rather than simply maximizing the total amount of drug administered.**

7. Clarithromycin Resistance and Pharmacodynamic Consequences

Clarithromycin is a macrolide that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit.

Resistance to clarithromycin in *H. pylori* is strongly associated with point mutations in the domain V region of the bacterial 23S rRNA gene. Important mutations include

Journal of Advances in Drug Research
ISSN: 2230-7761
www.jadr.co.in
Volume 17, Issue 04 | Received 12.09.2026 | Accepted 14.09.2026 | Online 19.09.2026

substitutions involving positions A2142 and A2143, which reduce antibiotic binding to the ribosomal target.

From a PK/PD perspective, resistance increases the MIC and therefore changes the exposure required for an antibacterial effect. If the achievable drug exposure is insufficient relative to the MIC, pharmacodynamic target attainment becomes unlikely.

This illustrates why susceptibility information is increasingly important. A treatment may be pharmacologically well designed but still ineffective if the infecting organism has a resistance mechanism that prevents adequate target engagement.

8. Metronidazole Resistance

Metronidazole is a prodrug that requires intracellular reduction to generate reactive metabolites capable of damaging bacterial DNA.

In *H. pylori*, resistance is associated particularly with alterations in nitroreductase pathways. Mutations in **rdxA** have been strongly linked to reduced activation of metronidazole, while alterations involving other reductase systems may also contribute.

The pharmacodynamic consequences are important because increasing systemic exposure cannot necessarily compensate for a fundamental defect in antimicrobial activation. This demonstrates a key distinction between **pharmacokinetic failure** and **microbiological resistance**.

Pharmacokinetic optimization aims to improve drug exposure. In contrast, when a resistance mechanism substantially compromises the biological target or activation pathway, the more appropriate scientific approach is to consider susceptibility-guided selection of an alternative antimicrobial class.

9. Role of Antimicrobial Susceptibility Testing

Antimicrobial susceptibility testing is increasingly relevant in the management of resistant *H. pylori*. The Maastricht VI/Florence consensus report emphasizes the importance of recognizing increasing antimicrobial resistance and supports susceptibility testing, including molecular approaches where appropriate.

Susceptibility testing provides microbiological information that can be integrated with PK/PD principles.

Conceptually:

susceptibility testing → MIC/resistance profile → exposure assessment → pharmacodynamic target → treatment strategy.

Molecular testing can be particularly useful for detecting known resistance-associated mutations when validated assays are available. Clarithromycin resistance, for example, may be identified through molecular detection of characteristic 23S rRNA mutations.

The integration of pharmacology and microbiology therefore represents an important direction for precision treatment.

10. Rifabutin-Based Approaches and the Pharmacological Rationale

Rifabutin is a rifamycin derivative that inhibits bacterial DNA-dependent RNA polymerase. Its use in *H. pylori* therapy has attracted interest because susceptibility to rifabutin remains relatively favorable in many settings compared with resistance to older commonly used agents.

Clinical studies have evaluated rifabutin-containing therapy in patients with previous treatment failures. A multicenter randomized study comparing rifabutin-based therapy with bismuth quadruple therapy demonstrated substantial eradication rates in treatment-

Journal of Advances in Drug Research
ISSN: 2230-7761
www.jadr.co.in
Volume 17, Issue 04 Received 12.09.2026 Accepted 14.09.2026 Online 19.09.2026

experienced populations, supporting rifabutin as one potential component of rescue strategies under appropriate clinical guidance.

The pharmacological importance of rifabutin illustrates a broader principle: when resistance to conventional antibiotics is common, selecting an agent with a different mechanism of action may restore antimicrobial activity. However, antibiotic stewardship remains important because unnecessary exposure can select additional resistance.

11. Duration and Adherence as PK/PD Determinants

Even when an antimicrobial has favorable pharmacological properties, treatment failure may occur if exposure is interrupted or inadequate.

Adherence directly affects the concentration-time profile. Missed doses can result in periods during which antimicrobial concentrations fall below pharmacodynamic targets. For time-dependent drugs, repeated interruptions may be particularly detrimental.

Treatment duration is also important because *H. pylori* colonization occurs in a complex gastric environment and the organism may occupy different physiological states. International guidelines have increasingly favored adequately long treatment courses, while emphasizing regimen-specific evidence. The 2024 ACG guideline, for example, recommends a 14-day optimized bismuth quadruple regimen in its preferred empiric treatment strategy when susceptibility is unknown.

From a pharmacological standpoint, adherence should therefore be understood as an essential determinant of antimicrobial exposure, rather than merely a behavioral variable.

12. Pharmacodynamic Interaction Between Acid Suppression and Antimicrobial Agents

The relationship between acid suppression and antibiotics is complex and should be considered a pharmacological interaction rather than a simple additive effect.

Acid suppression may:

1. raise intragastric pH;
2. alter bacterial physiology;
3. affect bacterial replication;
4. change the stability or activity of particular antimicrobial agents;
5. increase the consistency of the gastric environment during therapy.

Experimental work has demonstrated measurable pharmacodynamic effects of both antibiotics and acid pump inhibitors on *H. pylori*, supporting the concept that eradication therapy involves interaction between antimicrobial exposure and gastric physiology.

This interaction is particularly significant for amoxicillin-based approaches, where strong acid suppression may help create conditions favorable for sustained antibacterial activity.

13. Integrating PK/PD Principles with Resistance

A useful conceptual model for resistant *H. pylori* is:

bacterial susceptibility → MIC → achievable exposure → PK/PD target attainment → probability of eradication.

Resistance increases the MIC of an antimicrobial. If the pharmacokinetic profile of the drug cannot produce adequate exposure relative to the increased MIC, pharmacodynamic target attainment becomes unlikely.

Thus, treatment failure can theoretically arise through several pathways:

- increased antimicrobial resistance;
- inadequate gastric exposure;

Journal of Advances in Drug Research
ISSN: 2230-7761
www.jadr.co.in
Volume 17, Issue 04 Received 12.09.2026 Accepted 14.09.2026 Online 19.09.2026

- insufficient acid suppression;
- rapid drug metabolism;
- poor adherence;
- inappropriate treatment duration;
- drug-drug interactions;
- inadequate penetration into the gastric mucus;
- inappropriate empirical antibiotic selection.

This framework demonstrates why simply increasing the number of antimicrobial agents is not always the most rational response to treatment failure. Effective treatment design requires integration of microbiological, pharmacological, and clinical information.

14. Precision Treatment and Future Directions

The future of *H. pylori* eradication is increasingly likely to involve **precision antimicrobial therapy**.

Several areas deserve further investigation:

14.1 Molecular susceptibility testing

Rapid identification of resistance-associated mutations could permit earlier selection of effective treatment strategies.

14.2 PK/PD modeling

Population pharmacokinetic modeling can help characterize variability in drug exposure, while pharmacodynamic modeling can relate exposure to bacterial susceptibility.

14.3 Pharmacogenetics

The influence of CYP2C19 genotype on PPI exposure illustrates how host genetics can affect treatment efficacy. Pharmacogenetic strategies may become more relevant when differences in acid suppression have meaningful clinical consequences.

14.4 New acid-suppressive technologies

PCABs provide a useful example of how pharmacological modification of the gastric environment may improve antimicrobial effectiveness.

14.5 Microbiome preservation

Because eradication therapy can influence the intestinal microbiota and antibiotic resistome, future treatment development should consider not only eradication efficacy but also ecological consequences. The Maastricht VI consensus specifically emphasizes the interaction between *H. pylori* therapy and the gut microbiota.

15. Clinical and Research Implications

The increasing prevalence of antimicrobial resistance means that *H. pylori* eradication should no longer be viewed solely as a problem of selecting an antibiotic combination. It is a multidisciplinary pharmacological problem involving:

microbiology + pharmacokinetics + pharmacodynamics + gastric physiology + adherence + antimicrobial stewardship.

The most effective strategies are likely to be those that combine reliable susceptibility information with optimized drug exposure and adequate acid suppression.

Current international guidelines support this direction. The ACG guideline recommends resistance-aware selection and recognizes several modern therapeutic options, while the Maastricht VI/Florence consensus emphasizes susceptibility testing and rational first-line and rescue therapy selection in the setting of increasing resistance.

Journal of Advances in Drug Research

ISSN: 2230-7761
www.jadr.co.in

Volume 17, Issue 04 | Received 12.09.2026 | Accepted 14.09.2026 | Online 19.09.2026

Conclusion

The pharmacokinetic and pharmacodynamic optimization of *H. pylori* eradication therapy represents an important strategy for addressing the growing problem of antibiotic resistance. Pharmacokinetics determines the magnitude and duration of drug exposure, whereas pharmacodynamics determines whether that exposure is sufficient to inhibit or eradicate the infecting organism.

In *H. pylori* infection, systemic drug exposure alone is insufficient to explain therapeutic success. The gastric environment, intragastric pH, penetration into gastric mucus, bacterial susceptibility, antimicrobial mechanism of action, and treatment adherence all influence pharmacodynamic effectiveness. The pharmacology of acid suppression is particularly important because PPIs exhibit considerable interindividual variability related partly to CYP2C19 metabolism, whereas PCABs offer a more sustained approach to acid suppression.

Antimicrobial resistance changes the PK/PD relationship by increasing the exposure required to achieve a given antibacterial effect. Consequently, susceptibility testing and knowledge of local resistance patterns have become increasingly important. Molecular detection of resistance-associated mutations can further support individualized treatment planning.

Current evidence supports a transition from empiric, uniform approaches toward more rational and individualized strategies that integrate microbiological susceptibility, pharmacological characteristics, gastric physiology, and adherence. Future research should focus on PK/PD modeling, rapid molecular susceptibility testing, pharmacogenetics, novel acid-suppressive agents, and approaches that minimize disruption of the gut microbiome.

Overall, successful eradication of antibiotic-resistant *H. pylori* requires a multidisciplinary understanding of the interaction between the microorganism, the antimicrobial agent, the gastric environment, and the host. Pharmacokinetic and pharmacodynamic principles provide an important scientific foundation for this approach.

References

1. **Ashurova NG, Tolibov FF.** Impact of stress on female reproductive health: disorders and implications. *Journal of Education and Scientific Medicine*. 2025;5.
2. **Chey WD, Howden CW, Moss SF, Morgan DR, Greer KB, Grover S, Shah SC.** ACG Clinical Guideline: Treatment of *Helicobacter pylori* Infection. *Am J Gastroenterol*. 2024;119(9):1730–1753. doi:10.14309/ajg.0000000000002968.
3. **Farxodivich TF.** Cholestasis is a risk factor for the development of gallstone disease. *Nauchnyi Fokus*. 2024;2(21):317–321.
4. **Farxodivich TF.** Clinical characteristics of gastritis in digestive diseases. *Research Journal of Trauma and Disability Studies*. 2024;3(3):294–299.
5. **Farxodivich TF.** Infection of COVID-19 on cognitive functions. *Scientific Journal of Applied and Medical Sciences*. 2024;3(4):325–330.
6. **Furuta T, Graham DY.** Pharmacologic aspects of eradication therapy for *Helicobacter pylori* infection. *Gastrointest Clin North Am*. 2010. doi:10.1016/j.gtc.2010.08.007.

Journal of Advances in Drug Research

ISSN: 2230-7761
www.jadr.co.in

Volume 17, Issue 04 | Received 12.09.2026 | Accepted 14.09.2026 | Online 19.09.2026

7. **Hu Y, Huang XH, Zhou B, et al.** Vonoprazan and amoxicillin dual therapy for 14 days as the first-line treatment of *Helicobacter pylori* infection: a non-inferiority, randomized clinical trial. *Helicobacter*. 2024;29(1). doi:10.1111/hel.13045.
8. **Ishizaki T, Horai Y.** CYP2C19 genotypes in the pharmacokinetics/pharmacodynamics of proton pump inhibitor-based therapy of *Helicobacter pylori* infection. *Expert Opin Drug Metab Toxicol*. 2009. doi:10.1517/17425250903386251.
9. **Malfertheiner P, Megraud F, Rokkas T, et al.** Management of *Helicobacter pylori* infection: the Maastricht VI/Florence Consensus Report. *Gut*. 2022;71(9):1724–1762. doi:10.1136/gutjnl-2022-327745.
10. **Peng X, Yao JY, Ma YQ, et al.** Efficacy and safety of vonoprazan-amoxicillin dual regimen with varying dose and duration for *Helicobacter pylori* eradication. *Clin Gastroenterol Hepatol*. 2024;22(6):1210–1216. doi:10.1016/j.cgh.2024.01.022.
11. **Qiu S, Huang Y, Chen J, et al.** Vonoprazan-amoxicillin dual therapy with different amoxicillin administration regimens for *Helicobacter pylori* treatment: a randomized controlled trial. *Helicobacter*. 2024. doi:10.1111/hel.13118.
12. **Ru S, Jiang F, et al.** Global primary antibiotic resistance rate of *Helicobacter pylori* in recent 10 years: a systematic review and meta-analysis. *Helicobacter*. 2024. doi:10.1111/hel.13103.
13. **Tolibov FF.** Immune system: anatomy of the lymphatic system and mechanisms of immune response. *Zhurnal akademicheskikh issledovaniy novogo Uzbekistana*. 2024;1(2):55–58. doi:10.5281/zenodo.10688710.
14. **Tolibov FF.** Clinical and morphological correlations of liver cirrhosis. *Eur J Mod Med Pract*. 2024;4(11):515–520.
15. **Tolibov FF.** Extra-articular manifestations of rheumatoid arthritis. *Modern Science and Research*. 2025;4(5):1080–1087.
16. **Tolibov FF.** Impact of corticosteroid and immunosuppressive therapy on the course of chronic hepatitis: risks and prospects. *Modern Science and Research*. 2025;4(2):1123–1132.
17. **Tolibov FF.** Mononuclear cell infiltration accompanied by the progression of fibrotic and cirrhotic transformations in the liver tissue. *Modern Science and Research*. 2025;4(4):926–936. doi:10.5281/zenodo.15227499.
18. **Tolibov FF.** Pathomorphological abnormalities of the liver in patients infected with the hepatitis B virus. *Modern Science and Research*. 2025;4(3):1084–1093.
19. **Tolibov FF.** Violation of platelet aggregation and imbalance of hemostasis in patients with chronic viral hepatitis C. *New Day in Medicine*. 2024;6(68):264–268. Available from: https://newdayworldmedicine.com/en/article/3758
20. **Tolibov FF.** The syndrome of external secretory function insufficiency is a common complication of chronic pancreatitis. *American Journal of Bioscience and Clinical Integrity*. 2024;1(10):90–95.
21. **Tolibov FF, Shuhrat o'g'li RK.** Diabetik nevropatiya va uning zamonaviy terapiyasi. *Journal of Innovations in Scientific and Educational Research*. 2025;8(1):195–202.
22. **Influence of cytochrome P450 2C19 genotype on Helicobacter pylori proton pump inhibitor-amoxicillin-clarithromycin eradication therapy: a meta-analysis.** *Front Pharmacol*. 2021. doi:10.3389/fphar.2021.759249.